Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
AstraZeneca
AZN
|
+$677M |
| 2 |
Tesla
TSLA
|
+$374M |
| 3 |
Constellation Brands
STZ
|
+$357M |
| 4 |
NVIDIA
NVDA
|
+$292M |
| 5 |
Meta Platforms (Facebook)
META
|
+$264M |
Top Sells
| 1 |
Netflix
NFLX
|
+$892M |
| 2 |
Charter Communications
CHTR
|
+$838M |
| 3 |
AbbVie
ABBV
|
+$553M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$488M |
| 5 |
FedEx
FDX
|
+$418M |
Sector Composition
| 1 | Technology | 21.08% |
| 2 | Consumer Discretionary | 17.73% |
| 3 | Financials | 13.26% |
| 4 | Healthcare | 11.95% |
| 5 | Communication Services | 11.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Schneider National
SNDR
$4.19B
| $16.3M | 0.02% |
593,261
-695,218
| -54% | -$19.1M |
|
427
Spyre Therapeutics
SYRE
$991M
| $16.1M | 0.02% |
61,018
+814
| +1% | +$215K |
|
|
QTS
428
DELISTED
QTS REALTY TRUST, INC.
QTS
| $16M | 0.02% |
405,346
-160,703
| -28% | -$6.35M |
|
429
Ocular Therapeutix
OCUL
$2.23B
| $15.7M | 0.02% |
2,319,255
+26,503
| +1% | +$179K |
|
430
Coca-Cola
KO
$290B
| $15.6M | 0.02% |
355,626
-203,785
| -36% | -$8.94M |
|
|
SYNH
431
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $15.5M | 0.02% |
330,206
-301,014
| -48% | -$14.1M |
|
432
Acadia Healthcare
ACHC
$2.01B
| $15.4M | 0.02% |
377,446
+16,475
| +5% | +$674K |
|
|
X
433
DELISTED
US Steel
X
| $15.4M | 0.02% |
444,048
-93,516
| -17% | -$3.25M |
|
|
EIGR
434
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $15.3M | 0.01% |
41,883
+20,212
| +93% | +$7.4M |
|
435
Monro
MNRO
$491M
| $15.1M | 0.01% |
+260,269
| New | +$15.1M |
|
436
Alcoa
AA
$8.18B
| $15M | 0.01% |
319,022
-12,865
| -4% | -$603K |
|
437
Chemours
CC
$2.45B
| $14.8M | 0.01% |
334,179
+64,725
| +24% | +$2.87M |
|
|
NBLX
438
DELISTED
Noble Midstream Partners LP
NBLX
| $14.7M | 0.01% |
288,165
-2,488
| -0.9% | -$127K |
|
|
SHPG
439
DELISTED
Shire pic
SHPG
| $14.5M | 0.01% |
85,740
-84,773
| -50% | -$14.3M |
|
|
BPMC
440
DELISTED
Blueprint Medicines
BPMC
| $14M | 0.01% |
220,882
+12,408
| +6% | +$788K |
|
441
Huron Consulting
HURN
$2.39B
| $14M | 0.01% |
342,717
+17,703
| +5% | +$724K |
|
|
MMP
442
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $13.9M | 0.01% |
200,623
+129,331
| +181% | +$8.93M |
|
|
MNDT
443
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $13.7M | 0.01% |
+892,477
| New | +$13.7M |
|
444
Box
BOX
$4.76B
| $13.4M | 0.01% |
536,630
+26,921
| +5% | +$673K |
|
445
Constellium
CSTM
$1.99B
| $13.3M | 0.01% |
1,295,508
-78,153
| -6% | -$805K |
|
446
Cogent Biosciences
COGT
$1.78B
| $13.3M | 0.01% |
233,827
+9,638
| +4% | +$548K |
|
447
Philips
PHG
$26.9B
| $13.3M | 0.01% |
389,856
-5,991
| -2% | -$204K |
|
448
Nutrien
NTR
$27.7B
| $12.8M | 0.01% |
236,080
-12,727
| -5% | -$692K |
|
|
AM
449
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $12.8M | 0.01% |
434,536
-2,629
| -0.6% | -$77.6K |
|
450
Healthcare Services Group
HCSG
$1.15B
| $12.8M | 0.01% |
+295,404
| New | +$12.8M |
|